Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 52388

Wednesday, 07/10/2013 2:19:00 PM

Wednesday, July 10, 2013 2:19:00 PM

Post# of 257580
XTLB will once again trade on Nasdaq:

http://finance.yahoo.com/news/xtl-biopharmaceuticals-returns-nasdaq-174500572.html

XTLB once considered itself a player in HCV; some of its HCV drugs failed in early clinical trials (#msg-20222352), while an NS5A inhibitor was sold to Presidio Pharma in 2008 (#msg-27791536) and turned up in 2010 as PPI-461 (#msg-52296077). PPI-461 was shelved and superseded by a newer NS5A drug called PPI-668 (#msg-76993511).

One XTLB ADR will be equivalent to 20 home-market shares on the TASE in Israel.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today